Data demonstrate proprietary X-Editors engineered using Scribe’s CRISPR by Design™ approach are a promising gene editing platform for developing genetic medicines with high activity, specificity and ...
Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A year and a half into a collaboration with Biogen to develop CRISPR-based therapies, Scribe Therapeutics says the companies ...
Benjamin L. Oakes, PhD, Scribe Therapeutics co-founder, president, and CEO Scribe Therapeutics will partner with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, to develop in vivo CRISPR ...
Oral presentation on novel allosteric ELXR epigenetic silencer showcases Scribe’s development in achieving highly precise, potent, and durable target repression XE gene editor oral presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results